Given their popularity and the results that are being seen with their use, that is a question that is unlikely to get answered in a satisfactory way anytime soon and should be left to the individual and their prescribing physician.
Novo exits Hims & Hers partnership, citing deceptive marketing concerns Share via Novo Nordisk scrapped a partnership with Hims & Hers Health Inc
Consumers who have completed their own research and want to examine the full program details, current pricing, and published terms can do so by viewing the current MEDVi GLP-1 program offer (official MEDVi page)
If you have seen zero measurable change by week 6 while maintaining a caloric deficit, AOD-9604 may not be the right compound for your physiology
However, there are critical distinctions: Rodents have a much higher density of GLP-1 receptors on thyroid C-cells than humans Human thyroid C-cells show minimal GLP-1 receptor expression No causal link between semaglutide and thyroid cancer has been established in human clinical trials involving over 10,000 participants (Bjerre Knudsen et al., 2010, Endocrinology ) A large pharmacovigilance study published in Diabetes Care found no increased risk of thyroid cancer among GLP-1 receptor agonist users compared to other diabetes medications (Bezin et al., 2023, Diabetes Care ) Despite this reassurance, the following patients should avoid semaglutide: Those with a personal history of medullary thyroid carcinoma (MTC) Those with a family history of MTC Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) For patients with common hypothyroidism (typically Hashimotos thyroiditis or post-surgical hypothyroidism), these contraindications do not apply
